The company is tapping artificial intelligence and advanced analytics to build a “cognitive CDMO” connecting scientific knowledge with operational data.
The Frankfurt campus will add active pharmaceutical ingredient capacity, with production planned for 2032, as the company expands its global biologics and vaccine network.
The financing would support U.S. manufacturing of critical pharmaceutical ingredients, building on existing federal-backed efforts to expand biosynthesis production.
The technology transfer will prepare S2N.Bio’s autologous cell therapy for clinical manufacturing ahead of a planned first-in-human trial in 2027 in that country.
The integrated systems are designed to consolidate packaging operations that might otherwise require separate equipment for printing, verification, and sealing.
Explore how Consistone™ Yeast Extract UF may support CHO growth and productivity, with study data on batch and fed-batch performance, titer, and consistency.
Explore study data on peptone strategies for CHO growth, antibody titer, and consistency, with insights for batch and fed-batch processes and stalled productivity.
See how a supplement-based approach may support CHO productivity while keeping development options open, with study data to help guide your evaluation.
Lilly broke ground this week on a $6.5 billion active pharmaceutical ingredient facility that will make Foundayo, while Novo is expanding its oral Wegovy capacity.
Branded a “Chinese military” company by the Department of Defense, the CRDMO secured a legal victory last week against the 1260H designation, but the damage is done.
Proponents say using fermentation processes can help reduce America’s reliance on China and India for key starting materials and active pharmaceutical ingredients.
Not likely, argues Kymanox Executive Advisor Roger Lias, despite recent advances in continuous manufacturing for antibodies and other recombinant biologics.
Researchers are using machine learning and real-time process monitoring to improve bioreactor control and help manufacturers automate manual processes.
BMS said the system could not meet requirements to make commercial Breyanzi. Cellares claims it has manufactured GMP drug product in an FDA-regulated clinical program.
What needs to be taken into consideration when scaling up from the laboratory to full-scale production? Matt Smith, Sales Director at Silverson Machines explains which key factors...
The integration of chemical engineering into process development has transformed how companies scale, control, and optimize manufacturing for a new generation of therapies.
The draft guidance allows developers to leverage chemistry, manufacturing and controls data, as well as nonclinical and clinical information from other relevant products.
AI is helping life sciences manufacturers improve uptime, PM effectiveness, calibration planning, and reliability analysis. See where practical AI adds value in GMP asset management...
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Built-in ability to meet data integrity standards should be a central focus when selecting control systems and manufacturing execution systems for pharma manufacturing
The CRL relates to Good Manufacturing Practice observations at third-party manufacturer NerPharMa, and a request for additional commercial-scale consecutive batch data.
In response, Scholar Rock will remove the Bloomington fill-finish facility from its Biologics License Application with the agency and rely on a third-party provider.
As one of seven companies picked for the pilot, the integrated development and manufacturing organization says regulatory engagement cuts commercialization risk.
The agency selected contract manufacturers Cellares and Fujifilm Biotechnologies, as well as Big Pharma drugmakers Eli Lilly and Regeneron, for the pilot’s initial cohort.
Overseas markets take on increased attractiveness for India following President Trump’s threatened tariffs on generic drugs in 2028, finds data and analytics firm.
As injectable and oral GLP-1s evolve, pharma companies face tough choices about capacity, delivery platforms, outsourcing, and supply resilience, says CPHI Milan panel.
The share of newer FDA-approved innovator and biosimilar products whose production mix included a Chinese facility is rising, says data and analytics firm.
The drugmakers pledged to invest $19.6 billion collectively in U.S. manufacturing and provide discounts on select medicines in exchange for tariff exemptions.
Cell Therapies interior lab
